Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | HTR1A | P08908 | 6/20 | 0.61 |
| ▸ | DRD2 | P14416 | 6/20 | 0.61 |
| ▸ | HTR2A | P28223 | 5/20 | 0.61 |
| ▸ | DRD3 | P35462 | 5/20 | 0.61 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.61 |
| ▸ | DRD1 | P21728 | 3/20 | 0.61 |
| ▸ | DRD5 | P21918 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | HRH1 | P35367 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7653085 | 0.95 | CYP2D6 (0.70) | CYP2D6HTR1ADRD2HTR2ADRD3 | |
| SCHEMBL8011318 | 0.91 | DRD2 (0.69) | HTR1ADRD2HTR2ADRD3TMEM97 | |
| SCHEMBL1307372 | 0.88 | MAPT (0.58) | CYP2D6HTR1ADRD2HTR2ADRD3 | |
| SCHEMBL13875126 | 0.83 | KDM4E (0.69) | HTR1ADRD2HTR2ADRD3TMEM97 | |
| SCHEMBL11073634 | 0.83 | HSD17B10 (0.63) | CYP2D6HTR1ASIGMAR1HSD17B10KCNH2 | |
| SCHEMBL3197073 | 0.83 | CYP2D6 (0.63) | CYP2D6DRD2DRD3SIGMAR1HSD17B10 | |
| SCHEMBL5185951 | 0.83 | CYP2D6 (0.63) | CYP2D6HTR1ADRD2HTR2ADRD3 | |
| SCHEMBL9757260 | 0.83 | DRD2 (0.61) | HTR1ADRD2HTR2ADRD3TMEM97 | |
| SCHEMBL9757322 | 0.83 | HTR1A (0.61) | HTR1ADRD2HTR2ADRD3TMEM97 | |
| SCHEMBL2097950 | 0.83 | DRD2 (0.61) | HTR1ADRD2HTR2ADRD3TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2010-02-04 | — | — | US | claimed |
| EP-2057138-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | Pierre Fabre Medicament (FR) | 2009-05-13 | — | — | EP | claimed |
| WO-2008009741-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2008-01-24 | — | — | WO | claimed |
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2010-02-04 | — | — | US | disclosed |
| EP-2057138-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | Pierre Fabre Medicament (FR) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008009741-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2008-01-24 | — | — | WO | disclosed |
| US-5889010-A | PSYCHOLOGICAL DISORDERS; UROGENITAL DISORDERS; COGNITION ACTIVATORS; NERVOUS SYSTEM DISORDERS; VISION DEFECTS; CONGESTIVE HEART FAILURE; DRUG ABRUSE; PARKINSON'S DISEASE;ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | PFIZER INC. (US) | 1999-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | DRD3, CHRNA3, CHRM3 | CYP2D6 896/4885HTR1A 66/4885DRD2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.